RU2015111229A3 - - Google Patents

Download PDF

Info

Publication number
RU2015111229A3
RU2015111229A3 RU2015111229A RU2015111229A RU2015111229A3 RU 2015111229 A3 RU2015111229 A3 RU 2015111229A3 RU 2015111229 A RU2015111229 A RU 2015111229A RU 2015111229 A RU2015111229 A RU 2015111229A RU 2015111229 A3 RU2015111229 A3 RU 2015111229A3
Authority
RU
Russia
Application number
RU2015111229A
Other languages
Russian (ru)
Other versions
RU2015111229A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2015111229A publication Critical patent/RU2015111229A/ru
Publication of RU2015111229A3 publication Critical patent/RU2015111229A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2015111229/04A 2008-11-11 2009-11-10 Кристаллические формы гидрохлорида финголимода RU2015111229A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08168865 2008-11-11
EP08168865.7 2008-11-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2011123371/04A Division RU2549899C2 (ru) 2008-11-11 2009-11-10 Кристаллические формы гидрохлорида финголимода

Publications (2)

Publication Number Publication Date
RU2015111229A RU2015111229A (ru) 2015-11-20
RU2015111229A3 true RU2015111229A3 (https=) 2018-11-08

Family

ID=40521487

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2011123371/04A RU2549899C2 (ru) 2008-11-11 2009-11-10 Кристаллические формы гидрохлорида финголимода
RU2015111229/04A RU2015111229A (ru) 2008-11-11 2009-11-10 Кристаллические формы гидрохлорида финголимода

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2011123371/04A RU2549899C2 (ru) 2008-11-11 2009-11-10 Кристаллические формы гидрохлорида финголимода

Country Status (14)

Country Link
US (2) US8530522B2 (https=)
EP (1) EP2356090B1 (https=)
JP (4) JP2012508216A (https=)
KR (2) KR101393994B1 (https=)
CN (3) CN104788325A (https=)
AU (1) AU2009315736B2 (https=)
BR (1) BRPI0921826A2 (https=)
CA (1) CA2743232C (https=)
ES (1) ES2643161T3 (https=)
MX (1) MX2011004962A (https=)
PL (1) PL2356090T3 (https=)
PT (1) PT2356090T (https=)
RU (2) RU2549899C2 (https=)
WO (1) WO2010055028A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2621889B1 (en) 2010-10-01 2019-07-17 Synthon BV Process for making fingolimod hydrochloride crystals
PL2632889T3 (pl) 2010-10-28 2019-04-30 Mapi Pharma Ltd Związki pośrednie i sposób wytwarzania fingolimodu
WO2012071524A1 (en) 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
US9266816B2 (en) 2010-11-25 2016-02-23 Shilpa Medicare Limited Fingolimod polymorphs and their processes
EP2658840B1 (en) 2010-12-28 2019-07-03 Synthon BV Process for making fingolimod hydrochloride crystals
WO2012097330A2 (en) * 2011-01-14 2012-07-19 University Of Washington Compositions and methods for treating degenerative muscle conditions
EP2702034A4 (en) 2011-04-29 2015-03-25 Reddys Lab Ltd Dr PREPARATION OF FINGOLIMOD AND ITS SALTS
US9751834B2 (en) 2011-05-26 2017-09-05 Gri Bio, Inc. Oxygenated amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use
EP2739606B1 (en) 2011-05-26 2016-04-27 Jado Technologies GmbH Hydroxy-substituted amino and ammonium derivatives and their medical use
DK2809318T3 (da) 2011-05-26 2019-07-22 Gri Bio Inc Ammoniumholdige sulfonsyre-, phosphonsyre- og carboxylsyrederivater og disses medicinske anvendelse
WO2013019872A1 (en) 2011-08-01 2013-02-07 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
WO2013091704A1 (en) * 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
EP2945927A4 (en) * 2013-01-17 2017-01-18 Shilpa Medicare Limited Process for preparation of fingolimod and its salts
US9815772B2 (en) * 2013-03-05 2017-11-14 Biocon Limited Process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof
EP3027174B1 (en) 2013-07-29 2019-07-24 Aizant Drug Research Solutions Private Limited Pharmaceutical compositions of fingolimod
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
RU2627691C1 (ru) * 2016-07-06 2017-08-10 Олег Ростиславович Михайлов Кристаллическая η-модификация 2-амино-2-(2-(4-октилфенил)этил)пропан-1,3-диол гидрохлорида, способ её получения и фармацевтическая композиция на её основе
CN106860440A (zh) * 2017-01-16 2017-06-20 南京医科大学第二附属医院 盐酸芬戈莫德在制备治疗系统性红斑狼疮脑病药物中的应用
CN106667981B (zh) * 2017-01-16 2019-05-14 南京医科大学第二附属医院 盐酸芬戈莫德在制备治疗药物性肝损伤药物中的应用
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
WO2020245775A1 (en) * 2019-06-05 2020-12-10 Biocon Limited Crystalline forms of 2-amino-2-(2-(4-octylphenyl) ethyl) propane-1,3-diol
AU2020372647B2 (en) 2019-10-31 2026-02-05 Idorsia Pharmaceuticals Ltd Combination of a CXCR7 antagonist with an S1P1 receptor modulator
JP2024521882A (ja) 2021-05-31 2024-06-04 上海雲晟研新生物科技有限公司 フィンゴリモド薬用塩、製造方法、それを含む医薬組成物及び使用
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604229A (en) 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP4079505B2 (ja) * 1998-04-28 2008-04-23 田辺三菱製薬株式会社 2−アミノ−2−[2−(4−オクチルフェニル)エチル]プロパン−1,3−ジオールの新規な製造法
EP1457478B1 (en) * 1998-11-11 2017-07-19 Novartis AG Production of 2-amino-2-[2-(4-alkyl-phenyl)ethyl]propane-1,3-diols
PT1031347E (pt) * 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
CN1230421C (zh) * 1999-02-10 2005-12-07 三菱制药株式会社 酰胺化合物及其药物用途
CN1144779C (zh) * 1999-03-11 2004-04-07 杭州中美华东制药有限公司 制备2-[2-(4-烷基苯基)-乙基]-2-氨基-丙二醇的方法以及其中制得的中间产物
ES2322442T3 (es) * 2001-06-08 2009-06-22 Novartis Ag Tratamiento o profilaxis del rechazo de injertos de celulas productoras de insulina.
US20030144712A1 (en) * 2001-12-20 2003-07-31 Jackson Streeter, M.D. Methods for overcoming organ transplant rejection
PL372103A1 (en) * 2002-05-16 2005-07-11 Novartis Ag Use of edg receptor binding agents in cancer
GB0217152D0 (en) * 2002-07-24 2002-09-04 Novartis Ag Organic compounds
CA2521325C (en) 2003-04-08 2010-09-14 Novartis Ag Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
CN1212308C (zh) * 2003-07-24 2005-07-27 漆又毛 2-氨基-2-(2-(4-辛基苯基)乙基)-1,3-丙二醇盐酸盐的制备方法
CN1241903C (zh) * 2003-10-14 2006-02-15 马启明 制备2-对辛基苯乙基-2-氨基丙二醇的方法
TWI418350B (zh) * 2005-06-24 2013-12-11 Sankyo Co 含有ppar調節劑之醫藥組成物的用途
RU2008116578A (ru) * 2005-09-30 2009-11-10 Новартис АГ (CH) Применение ингибиторов dpp-iv для лечения аутоиммунных заболеваний и отторжения трансплантата
CN1310869C (zh) * 2005-11-22 2007-04-18 江苏吴中苏药医药开发有限责任公司 2-氨基-2-[2-(4-烷基苯基)乙基]-1,3-丙二醇的制备方法
CN100548968C (zh) * 2006-03-01 2009-10-14 徐州师范大学 一种制备2-对辛基苯乙基-2-氨基丙二醇盐酸盐的方法
ES2414205T3 (es) * 2006-06-02 2013-07-18 The Ohio State University Research Foundation Agentes terapéuticos para el tratamiento de linfoma de células del manto
KR20090057399A (ko) * 2006-09-26 2009-06-05 노파르티스 아게 S1p 조정제를 포함하는 제약 조성물
KR20110020928A (ko) * 2008-06-20 2011-03-03 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
EP2621889B1 (en) 2010-10-01 2019-07-17 Synthon BV Process for making fingolimod hydrochloride crystals

Also Published As

Publication number Publication date
WO2010055028A3 (en) 2010-07-08
WO2010055028A2 (en) 2010-05-20
EP2356090A2 (en) 2011-08-17
ES2643161T3 (es) 2017-11-21
AU2009315736A1 (en) 2010-05-20
PL2356090T3 (pl) 2017-12-29
US20110229501A1 (en) 2011-09-22
JP2014139179A (ja) 2014-07-31
JP2016028056A (ja) 2016-02-25
RU2549899C2 (ru) 2015-05-10
KR101393994B1 (ko) 2014-05-14
PT2356090T (pt) 2017-10-16
AU2009315736B2 (en) 2013-08-29
RU2011123371A (ru) 2012-12-20
JP2012508216A (ja) 2012-04-05
CA2743232C (en) 2015-12-29
JP2018035160A (ja) 2018-03-08
CN104788325A (zh) 2015-07-22
BRPI0921826A2 (pt) 2016-01-12
KR20130109254A (ko) 2013-10-07
CN107233336A (zh) 2017-10-10
US8530522B2 (en) 2013-09-10
CN102209705A (zh) 2011-10-05
MX2011004962A (es) 2011-05-30
US20140051766A1 (en) 2014-02-20
CA2743232A1 (en) 2010-05-20
RU2015111229A (ru) 2015-11-20
EP2356090B1 (en) 2017-07-05
KR20110069156A (ko) 2011-06-22

Similar Documents

Publication Publication Date Title
BR112016019572A2 (https=)
BRPI0909040A2 (https=)
BRPI0917573A2 (https=)
BRPI0908549B8 (https=)
BRPI0918697A2 (https=)
BRPI0917525A2 (https=)
BRPI0920750A2 (https=)
BRPI0919470A2 (https=)
BRPI0907698A2 (https=)
BRPI0917618A8 (https=)
BRPI0922455A2 (https=)
BRPI0923734A2 (https=)
BRPI0912727A2 (https=)
BRPI0922669A2 (https=)
BRPI0908285A2 (https=)
BRPI0910485A2 (https=)
BRPI0914750A2 (https=)
BRPI0919811A2 (https=)
BRPI0915616A2 (https=)
BRPI0908120A2 (https=)
BRPI0904541A8 (https=)
BRPI0912462A2 (https=)
BRPI0920914A2 (https=)
BRPI0922550A2 (https=)
BRPI0916284A2 (https=)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20191010